Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Natco Pharma settles...

    Natco Pharma settles patent litigation over generic version of anti-cancer drug Kyprolis

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-05-30T17:12:10+05:30  |  Updated On 16 Aug 2021 2:35 PM IST


    Kyprolis is the trade name for the generic drug Carfilzomib. The anti-cancer drug is a targeted therapy and is classified as a Proteasome Inhibitor.


    New Delhi: Natco Pharma recently said it has settled patent litigation with Onyx Therapeutics Inc in the US over a generic version of Kyprolis, an anti-cancer drug. The company said it has reached a settlement agreement with Onyx Therapeutics Inc related to generic versions of 10mg, 30mg and 60mg of Kyprolis, Natco Pharma said in a regulatory filing.


    Natco has tied up with Breckenridge Pharmaceutical Inc to market the product in the US.


    Read Also: Natco Pharma Q4 PAT plunges to Rs 120 crore



    "The parties have reached a settlement agreement and the district court case has been dismissed. By virtue of the settlement, Natco and Breckenridge have been granted a licence permitting the launch of their generic carfilzomib product on a date that is held as confidential in 2027 or sooner depending on certain occurrences," the company added.

    The company believes its 10mg ANDA is sole first to file and could be eligible for 180-day marketing exclusivity for the 10mg strength under certain circumstances, Natco said.

    Sales of Kyprolis stood at around USD 586 million for the year ended December 2018 in the US.

    Kyprolis is the trade name for the generic drug Carfilzomib. In some cases, health care professionals may use the generic name Carfilzomib when referring to the trade name Kyprolis. Kyprolis is a targeted therapy and is classified as a Proteasome Inhibitor.

    Based in Hyderabad, Natco Pharma was established in 1981 as a private limited company. The company develops, manufactures and markets finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). The company's major product categories include Domestic Formulations, International Formulations, APIs and Blockbusters.


    Read Also: Setback: Delhi HC restricts Natco Pharma from manufacturing cancer drug Ceritinib


    ANDAanti-cancer drugBreckenridge PharmaceuticalBSEcancercancer drugcancer therapycarfilzomibcarfilzomib injectiongeneric carfilzomib productgeneric druginhibitorKyprolislitigationNatco pharmaNatco sharesNew DelhiOnyxOnyx Therapeuticsproteasome inhibitorUnited States
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok